ESR1 and breast cancer: The TN cohort was chosen for three reasons: (a) to remove the confounding effects of ER and HER2, (b) taxanes are routinely given as standard of care in this population, and (c) the risk of recurrence is higher in TN breast cancer and therefore a large number of disease progression events were available for analysis.